Loading clinical trials...

Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Actinic Keratosis | Clinical Trials | Clareo Health

UNKNOWNNA

Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Actinic Keratosis

Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Actinic Keratosis#a Randomized, Open-label Trial

NCT04396184•Shanghai Dermatology Hospital

View on ClinicalTrials.gov

Summary

This study is being done to compare a new, continuous illumination and short Incubation time regimen of aminolevulinic acid photodynamic therapy#ALA-PDT) to a conventional regimen for treatment of Actinic Keratosis. The hypothesis is that the continuous illumination approach will be less or even no painful, but equally efficacious, as the old regimen.

Detailed Description

This study is being done to compare a new, continuous illumination and short Incubation time regimen of aminolevulinic acid photodynamic therapy#painless-PDT) to a conventional regimen for treatment of Actinic Keratosis. The hypothesis is that the continuous illumination approach will be less or even no painful, but equally efficacious, as the old regimen.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Clinical diagnosed with AK (OLSEN classification grade I, II, III), aged \> 18 years (Because no dosing or adverse event data are currently available on the use of topical aminolevulinic acid in patients \<18 years of age, children are excluded from this study);
•2. All patients are unfit and reluctant to undergo surgery for any reasons, and volunteered to participate in the study and ability to understand and the willingness to sign a written informed consent. Patents are willing to pay for the treatment, and agreed to take a picture of the skin lesions.

Exclusion Criteria

•1. Those who had ALA-PDT and any other studies that affect this study within 12 weeks ;
•2. There are other facial diseases that may affect the efficacy evaluation, such as other photodermatosis;
•3. Take phototoxic or photosensitizer within 8 weeks;
•4. Clinical and / or pathological prove that the tumor has invaded other organs or tissues;
•5. Serious immunocompromised persons;
•6. scar constitution;
•7. Patients are known to have skin photosensitivity, porphyria, or allergies to ALA, light or lidocaine;
•8. Persons are suffering from severe internal diseases, mental and mental illness, infectious diseases or pregnant or lactating women.

Locations (1)

Yunfeng Zhang

Shanghai, Jinan, China

Key Dates

Start Date

May 1, 2020

Primary Completion Date

April 30, 2021

Completion Date

April 30, 2021

Last Updated

May 20, 2020

Enrollment

ESTIMATED participants

Conditions

Actinic Keratosis

Interventions

Aminolevulinic acid photodynamic therapy

PROCEDURE

Contacts

Yunfeng Zhang, MD

CONTACT

18217422425 yunfeng0519116@aliyun.com

Haiyan Zhang, MD

CONTACT

18017336573 zhanghaiyan10842@163.com

The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

NCT06778434

Actinic KeratosisImipramine+1 more

View study

RECRUITING

Investigation of the Efficacy and Tolerability of Topical Applied Tirbanibulin on Actinic Keratoses With Downward-directed Proliferation Patterns

NCT06648447

Actinic Keratosis (AK)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 20, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Actinic Keratosis

Inclusion Criteria

Exclusion Criteria

The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

Investigation of the Efficacy and Tolerability of Topical Applied Tirbanibulin on Actinic Keratoses With Downward-directed Proliferation Patterns

The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy

Trial to Investigate GZ21T in Healthy Volunteers

Indoor Daylight Photodynamic Therapy is an Effective, First-line Treatment for AK, But Its Feasibility is Limited by the Time Required for the Illumination (2 Hours). Our Objective Was to Evaluate the Efficacy of Idl-PDT With an Illumination Time of 1 Hour Versus 2 Hours in the Treatment of Scalp AK

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis